Medtronic, Inc., a manufacturer of implantable medical devices, has announced the U.S. Food and Drug Administration’s (FDA’s) clearance and U.S. commercial release of its Medtronic EnPulse™ pacing system.
The Minneapolis, MN, U.S.-based company says its new EnPulse system incorporates an enhanced suite of features to help physicians better manage patients with slow heart rhythms and streamline the patient follow-up process, including the following:
Search AV +: An automatic and expanded search method that senses the patient's natural heartbeats before delivering pacing therapy, which may reduce unnecessary stimulation impulses in the ventricle, the heart's lower chamber. Recent clinical studies have suggested that reducing this pacing stimulation may reduce the patient's risk of developing heart failure. In addition, by reducing these impulses, the longevity of the device may be extended.
Quick Look II screen: A data display that allows clinicians to instantly access complete information about the patient's heart rhythm and pacemaker activity. In addition, new trend monitoring capabilities may reduce the amount of time needed to gather key information and shorten patient office visits.
Ventricular Response Pacing (VRP): This is a specialized form of pacing that may help the ventricles contract with a regular rhythm. Some patients who have episodes of atrial fibrillation -- a fast, disorganized heart rhythm originating in the heart's upper chambers -- also experience uneven heart contractions in the ventricles, which can cause palpitations and discomfort for the patient.
Back to Breaking News